Merck Sharp + Dohme Corp.

Craig A McKelvey

Bhagwant Rege

Sarah Geers

Dina Zhang

Laman L Alani

Soumojeet Ghosh

Justin Moser

Maria T Cruanes

Sutthilug Sotthivirat

Michael Lowinger

Robert F Meyer

Agam R Sheth

A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)&#x3e;10. 

Self-emulsifying formulations of CETP inhibitors

A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol. 

Polymer formulations of CETP inhibitors

Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.

CB-1 receptor modulator formulations

Growing community of inventors

Ambler, PA, United States of America

Craig A McKelvey